Jennison Associates
SAGE

Jennison Associates’s Sage Therapeutics SAGE Stock Holding History

Jennison Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-78,800
Closed -$5.9M – 717
2021
Q1 		$5.9M Buy
+78,800
New +$6.46M ﹤0.01% 461
2020
Q1 		– Sell
-80,200
Closed -$5.79M – 691
2019
Q4 		$5.79M Buy
80,200
+200
+0.3% +$24.6K 0.01% 421
2019
Q3 		$11.2M Buy
+80,000
New +$13.4M 0.01% 390
2017
Q4 		– Sell
-183,000
Closed -$11.4M – 686
2017
Q3 		$11.4M Sell
183,000
-64,200
-26% -$5.04M 0.01% 470
2017
Q2 		$19.7M Hold
247,200
– – 0.02% 412
2017
Q1 		$17.6M Buy
247,200
+127,200
+106% +$7.45M 0.02% 435
2016
Q4 		$6.13M Buy
+120,000
New +$5.66M 0.01% 504

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jennison Associates's SAGE Position: Q3 2021 in Review

Jennison Associates sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 582,120 shares — an estimated $33.1M sold.

Jennison Associates first reported a position in SAGE in Q4 2015 and held it in 23 quarters. The position peaked at $541M in Q2 2019. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Jennison Associates reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jennison Associates sold 582,120 Sage Therapeutics shares in Q3 2021, an estimated $33.1M.
  • Jennison Associates first reported a position in Sage Therapeutics in Q4 2015 and held it in 23 quarters.
  • Jennison Associates's Sage Therapeutics position peaked at $541M in Q2 2019.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Jennison Associates's 13F filing for Q3 2021, filed 9 Nov 2021.